4 Stocks To Buy On Monday If The Stock Markets Crash

The Dow Jones tumbled on Friday, following strong inflation data. This has raised the prospects of even a 75 basis points US Fed hike in interest rates. Indian markets and Asian markets are expected to fall, following a weak handover from Wall Street. Here are a few stocks that you could buy on Monday morning.

Biocon

Sharekhan has a buy call on the stock of Biocon with a price target of Rs 420 on the stock. "Biocon reported a strong performance for Q4FY22 and the results were in line with estimates. Further the commentary on the growth outlook was also encouraging. Basis the in line results we have largely retained our estimates for FY23E/ FY24E," the firm has said.

Laurus Labs

The firm also has a buy call on the stock of Laurus Labs with a price target of Rs 735. "Q4FY22 was muted quarter and results marginally missed estimates. However, the commentary on the growth and outlook was encouraging and provides ample visibility. Given the muted quarterly performance and a strong growth outlook, we have fine-tuned our FY23E/FY24E earnings estimates," the firm said.

Sanofi India

Sanofi India can rally up to Rs 9250 feels Sharekhan, which has placed a buy call on the stock with a price target of Rs 9250. "Operating margins for Q1CY22 expanded by 139 bps and was better than estimates, leading to adjusted PAT growing by 2.7% y-o-y and was ahead of estimates, however, the revenues declined marginally by 2.5% y-o-y. Basis this we have finetuned our estimates for CY22E/CY23E," the firm has stated.

Abbott India

Sharekhan has also recommended buying the stock of Abbott India for a price target of Rs 22780 on the stock. "Q4FY22 was a strong quarter with revenues and PAT staging a double-digit growth, reflecting the strong performance of acute therapies. Results were ahead of estimates. On the basis of strong growth prospects, and a high share of acute therapies (which are amongst the fastest growing in IPM), we have finetuned our estimates for FY23E/FY24E," the firm has said.

Long term prospects for pharma sector bight

According to Sharekhan, the Indian pharmaceutical companies are better placed to harness opportunities as they are competitive globally and hold a sizeable market share in most markets. Moreover, other factors such as 1) long-term opportunities in the US with increasing preference for specialty/complex generics (including biosimilars) and injectables, 2) Expected healthy growth in IPM, which is expected to stage close to double-digit growth in FY2023 as well, and 3) Emerging opportunities in the API space would be key growth drivers over the medium to long term; while in the near term, pricing pressures in the US and cost pressures could act as headwinds, though transient in nature. Collectively, this points towards a strong growth potential over the long term for Indian pharma companies
"The confluence of other factors including focus on specialty/complex products in addition to emerging opportunities in the API space would be key growth drivers. Collectively, though near-term headwinds are likely to sustain, longterm growth prospects are intact and, based on this, we have a Positive view on the sector," the firm has noted.